PTO/SB/06 (8-96)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENTEARDI ICATION FOR STATEMENT OF COMMERCE PATENT APPLICATION FEE DETERMINATION RECORD JNG 98-001 OTHER THAN CLAIMS AS FILED - PART I IIIN 1 3 2000 **SMALL ENTITY** SMALL ENTITY (Column 2) (Column 1) NUMBER FILED NUMBER EXTRA RATE **FEE RATE** FEE

> 33 remain in the application. The claim amendments herein track the amendments discussed with made Examiner in a telephonic interview on May 22, 2003. amended is οf these claims as now allowance and respectfully requested.

Claim Objections

Claims 6 and 30-33 stand objected to under 37 CFR §1.75(c) as being in improper form. The claims have been amended as requested by the Examiner to address objections under 37 CFR §1.75(c).

Rejection of Claims Under 35 U.S.C. §103

Claims 1-9, 16, 30, 32, and 33 stand rejected under 35U.S.C. §103(a) as being unpatentable over Watts et al. (U.S. 6,200,602). The Watts et al. '602 patent generally directed to a drug delivery composition for colonic delivery. In particular, Watts al. 1602 disclose a composition that prevents release of the polar drug until the formulation reaches the colon (column 6, lines 21-24).

By contrast, the presently claimed oral drug delivery composition provides a formulation for dissolving at least